Corcept Therapeutics (NAS:CORT) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Corcept Therapeutics Forward PE Ratio Related Terms
Corcept Therapeutics Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Corcept Therapeutics's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corcept Therapeutics Forward PE Ratio Chart
Corcept Therapeutics Annual Data
Trend
2018-12
2019-12
2020-12
2021-12
2022-12
2023-12
2024-12
2025-12
Forward PE Ratio
11.42
13.07
36.90
19.42
17.39
33.11
29.97
76.67
Corcept Therapeutics Quarterly Data
2018-06
2018-09
2018-12
2019-03
2019-06
2019-09
2019-12
2020-03
2020-06
2020-09
2020-12
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2022-09
2022-12
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
14.43
12.30
11.42
12.22
13.12
16.10
13.07
11.51
17.51
16.58
36.90
24.51
30.30
20.70
19.42
25.64
26.04
22.22
17.39
28.65
36.76
29.76
33.11
76.34
45.45
24.33
29.97
28.60
53.13
38.30
76.67
70.68
CORT vs PRAX, IBRX, NUVL: Forward PE Ratio Comparison
For the Biotechnology subindustry, Corcept Therapeutics's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corcept Therapeutics Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Corcept Therapeutics's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Corcept Therapeutics (CORT) has a Forward PE Ratio of 156.60 as of Jul. 07, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Corcept Therapeutics and its competitors. According to the industry distribution chart, Corcept Therapeutics ranks #318 out of 354 companies in the Biotechnology industry, placing it in the top 89.8%.
Is Corcept Therapeutics' Forward PE Ratio too high?
Corcept Therapeutics' current Forward PE Ratio is 156.60. The Biotechnology industry median Forward PE Ratio is 22.18. Corcept Therapeutics' value of 156.60 is 606% above this industry median. Based on the distribution chart, Corcept Therapeutics ranks #318 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corcept Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Forward PE Ratio compare to PRAX and IBRX?
According to the Biotechnology industry distribution chart, Corcept Therapeutics ranks #318 out of 354 companies for Forward PE Ratio. This places Corcept Therapeutics in the lower half of its industry. The industry median Forward PE Ratio is 22.18. Corcept Therapeutics' value of 156.60 is 606% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.18, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corcept Therapeutics's current Forward PE Ratio of 156.60 is 606% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Corcept Therapeutics and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corcept Therapeutics's current Forward PE Ratio is 156.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Corcept Therapeutics (CORT) is currently considered Significantly Overvalued. The stock's GF Value™ is $62.65, compared to a current price of $91.61 — trading 46.2% above its estimated fair value. The current Forward PE Ratio is 156.60 and 606% above the Biotechnology industry median of 22.18. Corcept Therapeutics' overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Corcept Therapeutics (CORT), the current Forward PE Ratio is 156.60 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corcept Therapeutics (CORT) Overvalued in 2026?
Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued.
The current stock price of $91.61 is trading 46.2% above its estimated GF Value™ of $62.65.
GuruFocus considers Corcept Therapeutics to be Significantly Overvalued.
Key valuation signals for CORT:
Forward PE Ratio: 156.60
GF Value™: $62.65 vs. price of $91.61 (46.2% above fair value)
Industry Position: 606% above the Biotechnology median (#318 of 354)
No single metric tells the full story. See the CORT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
82GF Score
Get the complete analysis for CORT
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CORT has been successfully added to your 